Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCR vs FCCam in Previously Untreated Fit Patients With CLL
NCT00564512Phase 3Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Nov 2007
- Primary completion
- Jan 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab, alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by French Innovative Leukemia Organisation. Started Nov 2007; status: completed.
02
Drugs
rituximabalemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00564512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00564512.